Natively inhibited Trypanosoma brucei cathepsin B structure determined by using an X-ray laser.
Redecke, L., Nass, K., DePonte, D.P., White, T.A., Rehders, D., Barty, A., Stellato, F., Liang, M., Barends, T.R., Boutet, S., Williams, G.J., Messerschmidt, M., Seibert, M.M., Aquila, A., Arnlund, D., Bajt, S., Barth, T., Bogan, M.J., Caleman, C., Chao, T.C., Doak, R.B., Fleckenstein, H., Frank, M., Fromme, R., Galli, L., Grotjohann, I., Hunter, M.S., Johansson, L.C., Kassemeyer, S., Katona, G., Kirian, R.A., Koopmann, R., Kupitz, C., Lomb, L., Martin, A.V., Mogk, S., Neutze, R., Shoeman, R.L., Steinbrener, J., Timneanu, N., Wang, D., Weierstall, U., Zatsepin, N.A., Spence, J.C., Fromme, P., Schlichting, I., Duszenko, M., Betzel, C., Chapman, H.N.(2013) Science 339: 227-230
- PubMed: 23196907 
- DOI: 10.1126/science.1229663
- Primary Citation of Related Structures:  
4HWY - PubMed Abstract: 
The Trypanosoma brucei cysteine protease cathepsin B (TbCatB), which is involved in host protein degradation, is a promising target to develop new treatments against sleeping sickness, a fatal disease caused by this protozoan parasite. The structure of the mature, active form of TbCatB has so far not provided sufficient information for the design of a safe and specific drug against T ...